Concord Biotech Limited vs Blue Jet Healthcare Limited
Last updated: 21 October 2026
Concord Biotech vs Blue Jet Healthcare: A MoneyDock Comparison
Concord Biotech Limited (CONCORDBIO.NS) and Blue Jet Healthcare Limited (BLUEJET.NS) are two prominent players in India's pharmaceutical and healthcare sectors. Concord Biotech specializes in the development and manufacturing of fermentation-based biopharmaceutical APIs, focusing on immunosuppressants and oncology drugs, making it a critical supplier for various life-saving medications. Blue Jet Healthcare, on the other hand, is a specialty chemicals company with a strong focus on contrast media intermediates and phygital healthcare solutions, serving diverse global markets including pharmaceuticals, diagnostics, and specialty pigments. Both companies operate in specialized niches within the broader healthcare ecosystem, demonstrating a commitment to research, development, and high-quality manufacturing, thus warranting a comparative analysis for investors looking to gain exposure to the Indian healthcare and specialty chemicals space.
Key Financial Metrics Comparison
| Metric | Concord Biotech Limited | Blue Jet Healthcare Limited |
|---|---|---|
| Current Price | ₹1270.00 | ₹495.40 |
| 52-Week High | ₹1579.40 | ₹626.25 |
| 52-Week Low | ₹1014.80 | ₹327.25 |
| 1-Year Return | -6.66% | -9.62% |
| Trailing P/E | N/A | N/A |
| Market Cap | N/A | N/A |
Analysis: Valuation, Returns, and Stability
When evaluating Concord Biotech and Blue Jet Healthcare, we are limited by the absence of trailing P/E and Market Cap data, which are crucial for a complete valuation assessment. However, we can still glean insights from other provided metrics.
Valuation: Without P/E and Market Cap, a direct comparison on valuation is challenging. However, looking at the current price relative to the 52-week range gives some perspective. Concord Biotech is trading at ₹1270.00, which is approximately 80% of its 52-week high of ₹1579.40 and significantly above its 52-week low of ₹1014.80. Blue Jet Healthcare, at ₹495.40, is also trading closer to its 52-week high of ₹626.25 (around 79%) and well above its 52-week low of ₹327.25. Both stocks appear to be off their lows, but neither has fully recovered to its 52-week peak. Without market capitalization, it's impossible to comment on which company is larger or potentially more undervalued or overvalued in absolute terms.
Returns: In terms of 1-Year Returns, both companies have delivered negative returns, indicating a challenging period for both stocks over the past year. Concord Biotech recorded a -6.66% return, which, while negative, is slightly better than Blue Jet Healthcare's -9.62%. This suggests that Concord Biotech has shown marginally more resilience or less depreciation in its share price over the last 12 months compared to Blue Jet Healthcare. For investors focused on recent performance, Concord Biotech currently holds a slight edge.
Stability: Stability can be inferred by examining the range between the 52-week high and low. Concord Biotech's range (₹1579.40 - ₹1014.80 = ₹564.60) is larger in absolute terms than Blue Jet Healthcare's (₹626.25 - ₹327.25 = ₹299.00). However, when considered proportionally to their current prices, Concord Biotech's range is about 44% of its current price, while Blue Jet Healthcare's range is about 60% of its current price. This relative volatility suggests that Blue Jet Healthcare has experienced a wider percentage fluctuation, potentially indicating higher volatility or lower price stability over the past year compared to Concord Biotech. From a price stability perspective, Concord Biotech appears to have traded in a relatively tighter band proportionally to its value.
MoneyDock Verdict
For Aggressive Investors: Both companies are operating in specialized and potentially high-growth sectors. Blue Jet Healthcare, with its higher proportional volatility over the past year and more significant drawdown in 1-year returns, might appeal to aggressive investors seeking a larger rebound potential if market conditions improve and the company executes well. However, this comes with higher risk.
For Conservative Investors: Given the current negative 1-year returns and the absence of key valuation metrics like P/E and Market Cap, a conservative investor might find both options challenging without further in-depth analysis of fundamentals, balance sheets, and future growth prospects. However, if forced to choose based solely on provided data, Concord Biotech shows slightly less negative returns and proportionally less volatility, which might be marginally more appealing from a risk perspective.
For Long-Term SIP Investors: For long-term SIP investors, both companies offer exposure to critical sectors. Concord Biotech's focus on biopharmaceutical APIs and Blue Jet Healthcare's on specialty chemicals (especially contrast media intermediates) represent essential and growing markets. Without valuation metrics, it's hard to ascertain if either is currently 'cheap' for accumulation. However, Concord Biotech's slightly better 1-year return and proportionally tighter trading range might indicate a company with slightly more consistent performance over the recent past, potentially making it a marginally less volatile SIP candidate. Long-term SIP investors should monitor the underlying business performance and future outlook closely for both.
Price data from Yahoo Finance. AI analysis by MoneyDock. Not financial advice — always do your own research before investing.